Liverpool HIV Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

No Interaction Expected

Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)

Rilpivirine (RPV)

Quality of Evidence: Very Low

Summary:

Coadministration with emtricitabine/tenofovir-DF has not been studied. Based on metabolism and clearance a clinically significant interaction with emtricitabine is unlikely. Coadministration of rilpivirine (150 mg once daily) and tenofovir-DF (300 mg once daily) decreased rilpivirine Cmax and Cmin by 4% and 1%, and increased AUC by 1%. Tenofovir Cmax, AUC and Cmin increased by 19%, 23% and 24%. No dose adjustment is necessary. [Note: this interaction study has been performed with a dose higher than the licensed dose for rilpivirine assessing the maximal effect on the co-administered drug. The dosing recommendation is applicable to the licensed dose of rilpivirine 25 mg once daily.]

Description:

Coadministration of tenofovir-DF (300 mg once daily) and a higher than the recommended dose of rilpivirine increased tenofovir AUC, Cmin and Cmax by 23%, 24% and 19% respectively. There was no change in rilpivirine AUC, Cmin or Cmax. No dose adjustment is required.

Edurant Summary of Product Characteristics, Janssen-Cilag Ltd, January 2019.

Coadministration of rilpivirine (150 mg once daily) and tenofovir-DF (300 mg once daily) decreased rilpivirine Cmax and Cmin by 4% and 1%, respectively, and increased AUC by 1%. Tenofovir Cmax, AUC and Cmin increased by 19%, 23% and 24%, respectively. No dose adjustment is needed for either drug.

Edurant US Prescribing Information, Janssen Therapeutics, May 2019.

The pharmacokinetic interaction between rilpivirine (150 mg once daily) and tenofovir-DF (300 mg once daily) was studied in 15 HIV-negative subjects. There was no relevant effect on rilpivirine exposure (3% decrease in Cmax, 2% increase in AUC and no change in Cmin). Tenofovir Cmax, AUC and Cmin increased by 21%, 24% and 24%. The increase in tenofovir is not clinically relevant and no dose adjustments are necessary.

Hoetelmans R, et al. Pharmacokinetic interaction between TMC278, an investigational non-nucleoside reverse transcriptase inhibitor, and tenofovir in healthy volunteers. 3rd IAS Conference on HIV Pathogenesis, Treatment and Prevention, Brazil, July 2005, abstract WePe3.3C15.

View all available interactions with Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking here.